Delta gD-2 is a vaccine candidate based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2).
Delta gD-2 is indicated to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2).
Extensive molecular and preclinical work has been completed for Delta gD-2, which induces unprecedented sterilizing immunity against both HSV-1 and HSV-2 challenge in multiple pre-clinical models.
Not only did the vaccine prevent disease, but Delta gD-2 also prevented the virus from establishing latency, which no herpes vaccine has shown before.
Latency refers to the ability of the herpes virus to remain dormant particularly in nerve tissue, often establishing lifelong infection with frequent subclinical or clinical reactivation.
Delta gD-2 acts via a novel mechanism of action that is mediated by non-neutralizing, Fc receptor activating antibodies to prevent both HSV-1 and HSV-2 infection with a wide range of clinical and laboratory isolates.
The broad protection observed in a variety of pre-clinical models combined with the potential for sterilizing immunity, as evidenced by the absence of latent virus, support the clinical development.
July 23, 2019: X-Vax Technology, Inc. (X-VAX ™) announced that it has raised $56 million in an upsized Series A financing with participation from strategic and institutional investors, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; and FF DSF VI, a scout investment vehicle out of Founders Fund.